DeepMed Research

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: imatinib mesylate
Drug: docetaxel

First Posted Date: 2002-05-30

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 28

Registration Number: NCT00038194

Locations: 🇺🇸
U.T. M.D. Anderson Cancer Center, Houston, Texas, United States

Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed Malignancies

Phase 2

Completed

Conditions: Wilms' Tumor
Osteosarcoma
Soft Tissue Sarcoma
Lymphoma
Leukemia

Interventions: Drug: Liposomal Vincristine

First Posted Date: 2002-05-30

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 29

Registration Number: NCT00038207

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Estramustine
Drug: Thalidomide
Drug: Paclitaxel (Taxol)

First Posted Date: 2002-05-30

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 40

Registration Number: NCT00038246

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Intravenous Estramustine With Taxol in Hormone Refractory Prostate Adenocarcinoma

Phase 1

Completed

Conditions: Prostate Cancer

Interventions: Drug: Estramustine
Drug: Taxol

First Posted Date: 2002-05-30

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 14

Registration Number: NCT00038168

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

First Posted Date: 2002-05-30

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00038181

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Thalidomide-Dexamethasone for Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Thalidomide
Drug: Dexamethasone

First Posted Date: 2002-05-29

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 83

Registration Number: NCT00038090

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

Phase 3

Completed

Conditions: Neuroendocrine Tumors
Metastases, Neoplasm

Interventions: Drug: I-131 Metaiodobenzylguanidine

First Posted Date: 2002-05-27

Last Posted Date: 2018-10-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00037869

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

rhTPO Mobilized Auto Cryo Platelets For GYN Patients Receiving Carboplatin

Not Applicable

Completed

Conditions: Neoplasms, Gynecologic

Interventions: Drug: Thrombopoietin
Procedure: Platelet-pheresis
Drug: Carboplatin

First Posted Date: 2002-05-27

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 33

Registration Number: NCT00038012

Locations: 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Phase 2

Terminated

Conditions: Leukemia, Myeloid, Philadelphia-Positive

Interventions: Drug: PEG-Intron

First Posted Date: 2002-05-27

Last Posted Date: 2018-11-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 1

Registration Number: NCT00037882

Locations: 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States

Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole

Not Applicable

Withdrawn

Conditions: Squamous Cell Carcinoma
Head and Neck Neoplasms
Metastases, Neoplasm

Interventions: Drug: 18F-fluoromisonidazole
Procedure: PET scan

First Posted Date: 2002-05-27

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00038038

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy